DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE) Property

Melting point:

107-109°C

Boiling point:

491.9±45.0 °C(Predicted)

Density 

1.23±0.1 g/cm3(Predicted)

storage temp. 

Sealed in dry,2-8°C

solubility 

DMF: 11 mg/ml; DMSO: 10 mg/ml; Ethanol: 12 mg/ml; PBS (pH 7.2): 0.25 mg/ml

form 

A solid

pka

12.22±0.60(Predicted)

color 

White to off-white

CAS DataBase Reference

53016-31-2

Safety

HS Code 

2937230000

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H351Suspected of causing cancer

H360May damage fertility or the unborn child

Precautionary statements

P201Obtain special instructions before use.

P308+P313IF exposed or concerned: Get medical advice/attention.

DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE) Chemical Properties,Usage,Production

Description

Ortho Evra@ is the first birth control transdermal patch and contains a combination of norelgestromin and ethinylestradiol. The patch can be applied to the buttocks, lower abdomen, upper torso or arms; changed weekly for 3 weeks, followed by a patch-free week. Norelgestromin is the active metabolite produced following oral administration of norgestimate, the progestin component of the contraceptive, Ortho-Cyclen^?. The half-life value of norelgestromin was approximately 28 h. Following application, norelgestromin rapidly appeared in the serum, reached a plateau by approximately 48h and was maintained at an approximate steady state throughout the wear period. Hepatic metabolites of norelgestromin included norgestrel and various hydroxylated and conjugated metabolites that were eliminated by renal and fecal pathways. Ortho Evra produced ovarian suppression and cycle control. It was significantly more effective in suppressing follicular development than the leading oral contraceptive Triphasil^? (ethinyl estradiol/levomorgestrel); was as effective in preventing pregnancies and had similar tolerability profile. The patch offers 99% efficacy when used appropriately, as shown by three clinical trials. However, a statistically significantly greater proportion of pregnancies occurred among women weighing 90 kg or more. Ortho Evra^? was well tolerated, with 2.6% of women discontinuing treatment due to mild to moderate reactions at the site of application. Thus, the patch combined the efficacy of oral contraceptives with the convenience of just once-weekly dosing.

Chemical Properties

White Solid

Originator

Johnson & Johnson (USA)

Uses

E/Z-17-Deacetylnorgestimate is a metabolite of Norgestimate. A contraceptive for birth control used by women.

Definition

ChEBI: Norelgestromin is a steroid. It derives from a hydride of an estrane.

brand name

ORTHOEVRA (R. W. Johnson); EVRA (R. W. Johnson) Note— Norelgestromin has appeared in the literature as 17- deacylnorgestimate.